Todd C. Skaar

发表

Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data

Salem Malikic, Süleyman Cenk Sahinalp, Ibrahim Numanagic, 2015, Bioinform..

A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer

Yadong Wang, Yunlong Liu, Pearlly Yan, 2011, BMC Systems Biology.

The Access Technology Program of the Indiana Clinical Translational Sciences Institute (CTSI): A model to facilitate access to cutting-edge technologies across a state

Todd C. Skaar, Kenneth Cornetta, Rob Orr, 2020, Journal of Clinical and Translational Science.

Qualitative study of system level factors related to genomic implementation

Joshua C. Denny, Mia A. Levy, Paul R. Dexter, 2018, Genetics in Medicine.

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects

Marylyn D. Ritchie, Joshua C. Denny, Teri E. Klein, 2018, Clinical pharmacology and therapeutics.

Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes

Todd C. Skaar, Hai Lin, Michael T. Eadon, 2016, Front. Pharmacol..

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Milan Radovich, Todd C. Skaar, Liang Cheng, 2016, Oncotarget.

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

Todd C. Skaar, David A. Flockhart, Daniel F. Hayes, 2016, The oncologist.

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

Norah Lynn Henry, Steffi Oesterreich, Todd C. Skaar, 2009, The Pharmacogenomics Journal.

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer

Steffi Oesterreich, Todd C. Skaar, David A. Flockhart, 2013, Breast Cancer Research and Treatment.